Showing papers by "Wyne P. Lee published in 2002"

TL;DR: It is shown that BR3 signaling promotes processing of the transcription factor NF-kappaB2/p100 to p52 and inhibiting the BR3-BAFF interaction has therapeutic ramifications, and the ligand binding interface of BR3 was investigated and found to reside within a 26 residue core domain.